LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • Measuring the Economic Footprint of the Biotechnology Industry in the European Union
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
        • BIOLEAD Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    EU biotech reaches record €42.2bn in GVA and €90bnexports, new edition WifOR Institute study shows

    17/11/2026

    PRESS RELEASE

    Brussels, 17 November 2026 - Gross value added (GVA) from EU biotech outputs reached a record €42.2 billion in 2024. The findings come from the 2026 edition of Measuring the Economic Footprint of the Biotechnology Industry in the European Union, conducted by the WifOR Institute on behalf of EuropaBio, now covering 2008–2024 and which tracks 117 products across sectors.

    In 2024, products across combined biotech sectors recorded average annual GVA growth of 4.7%, exceeding the EU economy-wide average of 3.6%.

    Biotech remains one of the EU's most economically productive technologies, generating €188,400 in GVA per employee in 2024, over 2.5 X the EU average, with healthcare outputs reaching €213,700 per employee.

    The EU's international trade position is also powered through biotech, with extra-EU biotechnology exports reaching €91.1 billion in 2024. Healthcare biotechnology exports remained substantially above 2020 levels following their pandemic-period peak, while industrial biotechnology exports followed a more consistent trend upwards.

    Employment growth in biotechnology in 2024 was almost four times higher than the EU average, whilst industry investment into R&D remains consistent at over €6bn per year.

    Dr Claire Skentelbery, Director General of EuropaBio, commented: "Biotechnology continues as an economic powerhouse in the EU. It is essential that policymakers at EU and Member State levels place this technology at the heart of ambitions for growth and resilience. It has significance far beyond economics as the world reorders itself for supply chain power and regional strength."

    LINK TO STUDY HOMEPAGE

    EU biotech reaches record €42.2bn in GVA and €90bnexports, new edition WifOR Institute study shows


    Download
    Share
    Communications Team

    Communications Team

    Related posts

    29/10/2026

    PRONAV Clinical joins EuropaBio: Supporting biotech innovation through clinical trial supply services


    Read more
    20/10/2026

    EU: Study on biomass and precision fermentation


    Read more
    30/09/2026

    Draghi Agenda in Focus: EuropaBio and BioPharmaChemIreland Gather to Discuss Accelerated Capital MarketReforms to Scale European Biotechnology


    Read more

    Important links

    • EU biotech reaches record €42.2bn in GVA and €90bnexports, new edition WifOR Institute study shows
    • PRONAV Clinical joins EuropaBio: Supporting biotech innovation through clinical trial supply services

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.